Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in ASCVD (ThyroHeart-Lipid Study)

Dyslipidemia Clinical Trial

Official title:

Thyroid Hormone Replacement for Subclinical Hypothyroidism and Dyslipidemia in Patients With Atherosclerotic Cardiovascular Diseases (ThyroHeart-Lipid Study)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03606824
• Other study ID #: 2018-zx7
• Status: Recruiting
• Phase: N/A
• Start date: March 25, 2019
• Est. completion date: May 31, 2020

Study information

• Verified date: March 2019
• Source: China National Center for Cardiovascular Diseases
• Contact: Chunli Shao, MD
• Phone: 0086-10-88396171
• Email: chunlishao[@]126.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

In ASCVD patients complicated with subclinical hypothyroidism, the percentage of those who did not reach the target of lipid-lowering therapy (LDL-C>1.8mmol/L) is usually higher than that in population with normal thyroid function. The present study aims to randomly compare two lipid-lowering therapeutic strategies (statins only vs. statins combined with thyroid hormone supplement).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 248
• Est. completion date: May 31, 2020
• Est. primary completion date: February 28, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Male or non-pregnant female;

2. Stable or unstable angina with evidence of myocardial ischemia; coronary angiography reveals stenosis lesions;

3. Subclinical hypothyroidism defined as mild TSH elevation within 5-10mIU/L and normal serum thyroid hormone levels within reference ranges;

4. Level of LDL-C is more than 1.8mmol/L before randomization.

5. Participate in the trial voluntarily and signs the written informed consent form.

Exclusion Criteria:

1. Those who have participated in other drug or therapy equipment clinical trials but did not reach the main study endpoint time limit;

2. Symptoms of severe heart failure (NYHA Class III and above) or left ventricular ejection fraction < 40% (ultrasound or left ventricle ngiography);

3. Pregnant or lactating women;

4. Complicated with severe organ dysfunction: large number of pericardial effusion; acute myocardial infarction; acute myocarditis; acute left heart failure; cardiogenic shock; severe arrhythmia, such as ventricular tachycardia, ventricular fibrillation, frequent atrial / ventricular premature beat, poor control of fast ventricular fibrillation, and bradycardia requiring pacemaker therapy, etc.

5. Patients who are unable to withstand lipid-lowering therapy or thyroid hormone replacement due to allergy to statins or levothyroxine;

6. Serum AST/ALT is three times higher than the upper limits of normal.

7. Patient's life expectancy is less than 12 months;

8. Those waiting for heart transplantation;

9. Patients who are deemed by the researchers to have low compliance and unable to abide by the requirements and complete the study.

Related Conditions & MeSH terms

• ASCVD
• Atherosclerosis
• Dyslipidemia
• Dyslipidemias
• Hypothyroidism
• Statin
• Subclinical hypothyroïdism

Intervention

Drug:
• Pitavastatin and placebo
The initial dosage of pitavastatin is 2mg, and it will be regulated according to the level of LDL-C and the upper limit is 4mg.Since the investigators are blind to the arms,the fake regulation of placebo dosage will be same as the Pitavastatin and levothyroxine group.
• Pitavastatin and levothyroxine
The initial dosage of pitavastatin is 2mg and the initial dosage of levothyroxine is 12.5ug. The dosage of levothyroxine will be regulated according to thyroid function test every 2-3 weeks. The regulation of pitavastatin dosage is same as the monotherapy group.

Locations

Country	Name	City	State
China	Fuwai Hospital, China National Center for Cardiovascular Diseases	Beijing

Sponsors (6)

Lead Sponsor	Collaborator
Shaochun.Li	Beijing Chao Yang Hospital, Beijing Friendship Hospital, Chinese Academy of Medical Sciences, Fuwai Hospital, Peking University Third Hospital, Xuanwu Hospital, Beijing

Country where clinical trial is conducted

China, 

References & Publications (6)

Gjedde S, Gormsen LC, Rungby J, Nielsen S, Jørgensen JO, Pedersen SB, Riis AL, Weeke J, Møller N. Decreased lipid intermediate levels and lipid oxidation rates despite normal lipolysis in patients with hypothyroidism. Thyroid. 2010 Aug;20(8):843-9. doi: 10.1089/thy.2009.0212. — View Citation

Lando HM, Burman KD. Two cases of statin-induced myopathy caused by induced hypothyroidism. Endocr Pract. 2008 Sep;14(6):726-31. — View Citation

Pazos F, Alvarez JJ, Rubiés-Prat J, Varela C, Lasunción MA. Long-term thyroid replacement therapy and levels of lipoprotein(a) and other lipoproteins. J Clin Endocrinol Metab. 1995 Feb;80(2):562-6. — View Citation

Pearce EN, Wilson PW, Yang Q, Vasan RS, Braverman LE. Thyroid function and lipid subparticle sizes in patients with short-term hypothyroidism and a population-based cohort. J Clin Endocrinol Metab. 2008 Mar;93(3):888-94. Epub 2007 Dec 11. — View Citation

Tzotzas T, Krassas GE, Konstantinidis T, Bougoulia M. Changes in lipoprotein(a) levels in overt and subclinical hypothyroidism before and during treatment. Thyroid. 2000 Sep;10(9):803-8. — View Citation

Willard DL, Leung AM, Pearce EN. Thyroid function testing in patients with newly diagnosed hyperlipidemia. JAMA Intern Med. 2014 Feb 1;174(2):287-9. doi: 10.1001/jamainternmed.2013.12188. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of LDL-C levels	Absolute change value of serum LDL-C levels between the baseline and 6-month assessment.	Baseline and 6-month.
Secondary	Changes of non-LDL lipid levels (TC, TG, HDL-C, non-HDL-C)	Absolute change value of serum non-LDL lipid levels (including TC, TG, HDL-C, non-HDL-C) between the baseline and 6-month assessment.	Baseline and 6-month
Secondary	LDL-C control rate	Percentages of patients who had LDL-C values below the treatment goal (LDL-C<1.8mmol/L) at 1-, 2-, 3- and 6-month assessment.	Baseline and 1-, 2-, 3- and 6-month assessment.
Secondary	Dosage of treatment drugs (pitavastatin and levothyroxine)	The dosage of pitavastatin and levothyroxine in combination group at 6-month assessment; The dosage of pitavastatin in control group at 6-month assessment	At 6-month assessment.
Secondary	Levels of thyroid hormones at 6-month assessment	Levels of thyroid hormones (thyroid-stimulating hormone, free triiodothyronine, free thyroxine, total triiodothyronine, and total thyroxine) at 6-month assessment	At 6-month assessment.
Secondary	Rates of major adverse cardiac and cerebrovascular events at 6-month assessment	Rates of major adverse cardiac and cerebrovascular events (MACCE, including cardiac death, myocardial infarction, target vessel revascularization and cerebrovascular events) during 6 months follow-up.	During 6-month follow-up.
Secondary	Levels of glutamic-pyruvic transaminase (ALT) at 1-, 2-, 3- and 6-month assessment	Safety endpoint: live injury parameters, including levels of glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST).	Baseline and 1-, 2-, 3- and 6-month assessment.
Secondary	Levels of glutamic-oxaloacetic transaminase (AST) at 1-, 2-, 3- and 6-month assessment	Safety endpoint: live injury parameters, including levels of glutamic-pyruvic transaminase (ALT) and glutamic-oxaloacetic transaminase (AST).	Baseline and 1-, 2-, 3- and 6-month assessment.
Secondary	Levels of serum creatine kinase (CK) at 1-, 2-, 3- and 6-month assessment	Safety endpoint: muscle injury parameter——serum creatine kinase (CK)	Baseline and 1-, 2-, 3- and 6-month assessment.